Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APAF1 | O14727 | 1/20 | 0.53 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.41 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.41 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10767735 | 1.00 | APAF1 (0.53) | APAF1GABRR1CYP1A2FOLH1NAALAD2 | |
| SCHEMBL25543906 | 0.81 | APAF1 (0.36) | APAF1CYP1A2ADRB2MEN1KMT2A | |
| SCHEMBL3235189 | 0.78 | APAF1 (0.48) | APAF1GABRR1CYP1A2FOLH1NAALAD2 | |
| SCHEMBL25548515 | 0.78 | APAF1 (0.48) | APAF1GABRR1CYP1A2FOLH1NAALAD2 | |
| SCHEMBL11316232 | 0.78 | APAF1 (0.47) | APAF1GABRR1CYP1A2FOLH1NAALAD2 | |
| SCHEMBL11505440 | 0.78 | APAF1 (0.47) | APAF1GABRR1CYP1A2FOLH1NAALAD2 | |
| SCHEMBL7402444 | 0.77 | TET2 (0.42) | CYP1A2KDM4EPOLBMAPTBLM | |
| SCHEMBL10308384 | 0.77 | APAF1 (0.34) | APAF1KDM4EPOLBMAPTBLM | |
| SCHEMBL7402442 | 0.77 | TET2 (0.42) | CYP1A2KDM4EPOLBMAPTBLM | |
| SCHEMBL19090802 | 0.77 | TET2 (0.42) | CYP1A2KDM4EPOLBMAPTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20210246344-A1 | Biological buffers with wide buffering ranges | DALY THOMAS (US) | 2021-08-12 | — | — | US | disclosed |
| US-20210179580-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PD1/PD-L1 ACTIVATION | Jubilant Prodel LLC | 2021-06-17 | — | — | US | disclosed |
| US-20200071582-A1 | Biological Buffers with Wide Buffering Ranges | TPAT IP LLC | 2020-03-05 | — | — | US | disclosed |
| US-8334402-B2 | Biological buffers with wide buffering ranges | TPAT IP LLC | 2012-12-18 | — | — | US | disclosed |
| US-8034951-B2 | Biological buffers with wide buffering ranges | TPAT IP LLC | 2011-10-11 | — | — | US | disclosed |
| US-20110137076-A1 | Biological Buffers with Wide Buffering Ranges | TPAT IP LLC | 2011-06-09 | — | — | US | disclosed |
| US-7939659-B2 | Biological buffers with wide buffering ranges | TPAT IP LLC | 2011-05-10 | — | — | US | disclosed |
| US-20100190993-A1 | Biological Buffers with Wide Buffering Ranges | TPAT IP LLC | 2010-07-29 | — | — | US | disclosed |
| US-20100099868-A1 | Biological Buffers with Wide Buffering Ranges | TPAT IP LLC | 2010-04-22 | — | — | US | disclosed |
| US-20090131384-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH ER STRESS | SYNDEXA PHARMACEUTICALS CORPORATION (US) | 2009-05-21 | — | — | US | disclosed |
| EP-0219852-B1 | CHARTREUSIN DERIVATIVES, SALTS THEREOF, ANTITUMOROUS COMPOSITIONS CONTAINING THE SAME, AND PROCESSES FOR PRODUCING THE SAME | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1992-02-05 | — | — | EP | disclosed |
| US-5064945-A | Antitumor Agents | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1991-11-12 | — | — | US | disclosed |
| US-4927919-A | ANTITUMOR AGENTS | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1990-05-22 | — | — | US | disclosed |
| EP-0159708-B1 | CHARTREUSIN DERIVATIVES, SALTS THEREOF, ANTITUMOROUS COMPOSITIONS CONTAINING THE SAME, AND PROCESSES FOR PRODUING THE SAME | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1989-12-13 | — | — | EP | disclosed |
| US-4760136-A | Chartreusin derivatives and salts thereof | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1988-07-26 | — | — | US | disclosed |
| EP-0159708-A2 | Chartreusin derivatives, salts thereof, antitumorous compositions containing the same, and processes for produing the same | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1985-10-30 | — | — | EP | disclosed |
| US-4217238-A | BASIC SALT, SCRUBBING | EXXON RESEARCH & ENGINEERING CO. (US) | 1980-08-12 | — | — | US | disclosed |
| US-4094957-A | CARBON DIOXIDE | EXXON RESEARCH & ENGINEERING CO. (US) | 1978-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179580-A1 | PYRIMIDINE DERIVATIVES AS INHIBITORS OF PD1/PD-L1 ACTIVATION | PDCD1, CD274, PDCD1LG2 | APAF1 888/4885GABRR1 4195/4885CYP1A2 241/4885 |
| US-20100099868-A1 | Biological Buffers with Wide Buffering Ranges | PEF1, SLC7A1, PLPBP | APAF1 1850/4885GABRR1 625/4885CYP1A2 4877/4885 |
| US-20090131384-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH ER STRESS | NR1H3, NR1H2, SREBF1 | APAF1 1784/4885GABRR1 992/4885CYP1A2 2612/4885 |
| US-20100190993-A1 | Biological Buffers with Wide Buffering Ranges | PEF1, SLC7A1, PLPBP | APAF1 1850/4885GABRR1 625/4885CYP1A2 4877/4885 |
| US-20200071582-A1 | Biological Buffers with Wide Buffering Ranges | PEF1, SLC7A1, PLPBP | APAF1 1850/4885GABRR1 625/4885CYP1A2 4877/4885 |
| US-20110137076-A1 | Biological Buffers with Wide Buffering Ranges | PEF1, SLC7A1, PLPBP | APAF1 1850/4885GABRR1 625/4885CYP1A2 4877/4885 |
| US-20210246344-A1 | Biological buffers with wide buffering ranges | PEF1, SLC7A1, PLPBP | APAF1 1886/4885GABRR1 636/4885CYP1A2 4877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.